GT Biopharma Inc (OTCMKTS: GTBP) is one of my favorite stocks in the coronavirus space. The company’s TriKE, an NK cell engager, has generated incredibly positive data. While this data was not in a COVID-19 patient, it is the same technology and same response that we hope to see among COVID-19 patients, making the data hard to ignore. Here’s what’s going on:
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
GTBP Stock Is One To Watch After Positive Data
In a press release issued earlyt his morning, GT Biopharma said that it has been given approval and started retreatment on Monday, of the first patient to receive GTB-3550 in a Phase I/II clinical trial for the treatment of AML.
Importantly, the company said that the patient achieved a stable disease response with the number of AML blasts observed. Moreover, no adverse events took place.
GTBP also said that it observed an increase in the patient’s total NK cell population, the cells that fight against cancer and other illnesses. At the same time, there was no appreciable increase of any hyper-active T-cell population which could have resulted in cytokine storm or other t-cell associated toxicities.
In a statement. Anthony Cataldo, Chairman and CEO At GTBP, had the following to offer:
We are pleased to commence retreatment of the initial patient, and look forward to continuing enrollment of new patients entering the clinical trial as our pause to free hospital beds for potential coronavirus patients abates. We remain optimistic that GTB-3550 will continue to demonstrate therapeutic benefit in AML cancer patients with advanced disease.” Mr. Cataldo added, “We believe our AML TriKE™ will provide much better economics to the patients and our company then CAR T-cell therapies (Celegen and Gilead Sciences) that involve expensive adoptive cell therapy protocols.
The robustness of the TriKE™ platform allows us to develop therapeutics for the treatment of other cancers and certain infectious diseases including HIV and coronavirus infections. We most recently announced our Coronavirus TriKE™ partnership with USA-based manufacturing company Cytovance Biologics (a division of multi-billion dollar Shenzhen Hepalink Pharmaceutical Group of companies (002399:CH Shenzhen, CHINA). We are excited by the progress of our TriKE™ platform and will continue to update our shareholders as the Coronavirus TriKE™ and GTB-3550 TriKe™ continue to progress.
What Does This Have To Do With COVID-19?
As mentioned above, GT Biopharma is one of my favorite stocks in the coronavirus space. So, what does this have to do with COVID-19? Well… EVERYTHING!
GTB-3550 uses the same technology that the company is using to fight against the virus. The goal here is to enhance IL-15, an NK cell-stimulating cytokine, causing NK cells to act in a more robust way to fight off disease.
In this particular patient, the treatment achieved stable disease at the lowest dose. This patient was heavily pretreated and lived with a grim prognosis.
While AML and coronavirus are two very different illnesses, if GTBP is effective in increasing activity of NK cells in this patient, it will likely be effective in increasing NK cell activity in COVID-19 patients. Should this take place, the NK cells would attack the COVID-19 infected cells within the body, effectively treating the condition.
So, while the data released today was from an AML patient, this positive data is a big win in the COVID-19 space as well.
In my opinion, GTBP is in a great spot at the moment. The company’s treatment is likely to be effective in the coronavirus space. Moreover, beyond COVID-19, the company’s treatment is proving to be effective in AML. Of course, an approval in either of these conditions could turn the company into a major player in biotech. So, there’s a great opportunity here for investors.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
Get Free Alerts
Join our free mailing list to receive stock alerts!
This website/newsletter is owned, operated and edited by CNA Finance, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “CNA Finance” refers to CNA Finance, LLC. This webpage/newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to publish information and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners do not own any shares in stocks mentioned unless stated in page disclosures. If we own any shares we will list the information relevant to the stock and number of shares here. CNA Finance, parent company to Alpha Stock News, receives payment to publish content and promote publicly traded companies. Pursuant to an agreement between CNA Finance and GT Biopharma, CNA Finance has been hired for a period beginning on 3/1/20 and ending on 4/31/20 to conduct digital advertising and marketing and publicly disseminate information about GTBP via Websites and Email. We have an agreement and are currently owed $15,000 by via bank wire transfer to cover the cost of content production. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated digital outreach efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of digital outreach marketing, which may end as soon as the marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct and GT Biopharma has not approved the content of this site. Furthermore, CNA Finance often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.